GlycoMimetics Inc.

11/23/2021 | Press release | Distributed by Public on 11/23/2021 15:38

Apollomics Inc. Doses First Patient in Phase 3 Clinical Trial in China of GlycoMimetics’ Uproleselan for the Treatment of AML